PTC/SB/08A (07-05)
Approved for use through 07/31/2006.OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information under scortains a valid OMS control number.
Substitute for form 1449APTO
Commission of Known

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	Complete	II KIIOWII
ı	Application Number	10/534,660
	Filing Date	11/28/2005
	First Named Inventor	Gunther Harth
	Group Art Unit	1617
	Examiner Name	Unassigned
Ī	Attorney Docket Number	51326-00005 NAT

			U.S. PATENT DOCUM	ENTS	
Examiner Initials	Cite No.1	Document Number  Number-Kind Code <sup>2 (Kinser)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		3,888,837	06/10/75	Tsumita et al.	
		3,943,119	03/09/76	Tsumita et al.	
		4,123,427	10/31/78	Dniel	
		4,285,931	08/25/81	Limjuco et al.	
		4,460,503	07/17/84	Savrda et al.	
		4,724,144	02/09/88	Rook et al.	
		4.777.130	10/11/88	Maes	
		4.889.800	12/26/89	Shinnick et al.	
		4.906.742	03/06/90	Young et al.	
		4.952.395	08/28/90	Shinnick et al.	
		4,965,192	10/23/90	Maes	
		4,976,958	12/11/90	Shinnick et al.	
		5,108,745	04/28/92	Horwitz	
		5,154,923	10/13/92	Van Eden et al.	
		5,169,940	12/08/92	Patarroyo	
		5,171,839	12/15/92	Patarrovo	
		5,225,324	07/06/93	McFadden et al.	
		5,254,459	10/19/93	Patarroyo	
		5,268,170	12/07/93	Van Eden et al.	
		6,013,660	01/11/00	Horwitz et al.	

				FOREIG	IN PATENT DOCUMEN	ITS		
			oreign Patent Docum		47.1412/15	G. P. Sadron	Pages, Columns, Lines, Where	70
Examiner Initials	No.1	Office <sup>3</sup>	Number	Kind Code <sup>5</sup>	Date of Publications of Cited Documents MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	100
		EP	0499003	$\Box$	08/1992			
		EP	0519218		12/1992			Г
		GB	2239246		06/1991			
		WO	85/03639	-	08/1985			

	WO	00/00009	00/1900		
-	_				
Examiner				Date	
Signature				Considered	

TOWARD In life in the recommendation, whether and clation is another was with SEPE DD. One for through clitical for the continence and one continence location group of the time with a second continence and one continente a

PTC/S8/08A (07-05)
Approved for use through 07/31/2006 OMB 0551-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449APTO

Complete if Known

## INFORMATION DISCLOSURE

(use as many sheets as necessary)

Application Number	10/534,660
Filing Date	11/28/2005
First Named Inventor	Gunther Harth
Group Art Unit	1617
Examiner Name	Unassigned
Attorney Docket Number	51326-00005 NAT

					IN PATENT DOCUMEN	ITS		
			oreign Patent Docum				Pages, Columns, Lines, Where	Ι.
Examiner Initials	No.1	Office <sup>3</sup>	Number <sup>e</sup>	Kind Code <sup>5</sup>	Date of Publications of Cited Documents MM-DD-YYYY	Name of Patentee or Applicant of Cried Document	Relevant Passages or Relevant Figures Appear	۲
		wo	88/02027		03/1988	-	1,77	1
		WO	88/05823		08/1988	1		$\vdash$
		WO	88/06626		09/1988			
		WO	89/05825		06/1989			
		wo	89/12455		12/1989			T
		wo	90/00594		01/1990			Т
		wo	90/02564		03/1990			Г
		wo	90/10449		09/1990			Т
		wo	90/15873		12/1990			Г
		wo	91/04272		04/1991			Г
		wo	91/14448		10/1991			Г
		WO	92/01783		02/1992			Г
		wo	92/01796		02/1992			Г
		WO	92/04462		03/1992			Г
		WO	92/16628		10/1992			Г
		WO	92/21376		12/1992			
		WO	92/21697		12/1992			
		WO	92/22326		12/1992			
		WO	93/07897		04/1993			
		WO	93/14118		07/1993			
		WO	93/14789		08/1993			L
		WO	94/02508		02/1994			L
		wo	95/01440		01/1995		L	L
		WO	95/01441		01/1995			Γ
		WO	95/14713		06/1995			L
		wo	04/45539		06/2004			

Examiner	Date	
Signature	Considered	

TOURNET, that is demonst construct, whether and claims in continuous and META BILL has been being distinct for incommence and secretarial productions of the continuous and an extension of the continuous and the continuous

PTO/SB/084 (07-05) Approved for use through 07/31/2006 OMB 0651-0031

51326-00005 NAT

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Complete if Known

	00114	noto il resonti
	Application Number	10/534,660
INFORMATION DISCLOSURE	Filing Date	11/28/2005
STATEMENT BY APPLICANT	First Named Inventor	Gunther Harth
	Group Art Unit	1617
(	Examiner Name	Unassigned

Attorney Docket Number

of

Sheet

Examiner

Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), filte of the article (when appropriate), filte of the fem (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Abbott et al., "Structure prediction and active site analysis of the metal binding determinants in y-glutamylcysteine synthetase," J. Biol. Chem. 276:42099-107 (2001)	
		Bartsch et al., "Stereospecific production of the herbicide phosphinothricin (Glufosinate) by transamination: cloring, characterization, and overexpression of the gene encoding a phosphinothricin-specific transaminase in Escherrichia coli," App. Environ. Microbiol. 56:7-12 (1990)	
		Campbell et al., "Analytical and Preparative Separation of Diastereomers of L-Buthionine- SR-Sulfoximine, a Potent Inhibitor of Glutathione Biosynthesis," Anal. Biochem. 194:268- 77 (1991)	
		Chambertin et al., "Design and synthesis of conformationally constrained inhibitors of highly-affinity, sodium dependent glutamate transporters," Meth. Enzymol. 296:175-89 (1998)	
		Cooper et al., "Enzymatic reactions of methionine sulfoximine. Conversion to the corresponding a-minno and a-keto acids and to a-ketobuyrate and methane sulfinimide," J. Blot. Chem. 251:6674-82 (1976)	
		Database CAPLUS, Chemical Abstracts on STN, (Columbus Ohio, USA), Abstract No. 50:49285, SVACHULOVA, Effect of L-Ascorbie Acid on the Growth and Metabolism of Mycobacteria Tuberculosis, Rozhledly Tuberk, 1956, Vol. 16, pp. 203-206	
		Eisenberg et al., "Structure-function relationships of glutamine synthetases," Biochim. Biophys. Acta. 1477:122-45 (2000)	
		Gershoff et al., "The relative effect of methionine sulfoximine on different animal species," J. Nutr. 45:451-8 (1951)	
		Gill et al., "Multicopy crystallographic refinement of a relaxed glutamine synthetase from Mycobacterium tuberculosis highlights flexible loops in the enzymatic mechanism and its regulation," Biochemistry 41:9863-72 (2002)	
		Gill et al., "The crystal structure of phosphinothricin in the active site of glutamine synthetase illuminates the mechanism of enzyme inhibition," Biochemistry 40:1903-12 (2001)	
		Griffith "Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione biosynthesis," J. Biol. Chem. 257:13704-12 (1982)	

Signature "DWING It that in the considered, wholve or not classics in continuous with SPCP CRD. Date fine framage classics if not in continuous and not considered. Include capy of this form with next communication is applicated. Applicated in continuous and applicated in the continuous and applicated ST. It's present, a "applicated in to place a close continuous and applicated ST. It's present, a "applicated in the place as close continuous and applicated ST. It's present, a "applicated in a place a close continuous and the ST. It's present, a "applicated in a place a close continuous and the ST. It's present, a "applicated in a place a close continuous and the ST. It's present, a "applicated in a place a close continuous and the ST. It's present, a "applicated in a place a close continuous and the ST. It's present, a "applicated in a place a close continuous and applicated in a place a close continuous and applicated in the state of the ST. It's present, a "applicated in a place a close continuous and applicated in the state of the ST. It's present, a "applicated in a place a close continuous and applicated in the state of the ST. It's present, a "applicated in a place a close continuous and applicated in the state of the ST. It's present, a "applicated in a place a close and applicated in the state of the ST. It's present, a "applicated in a place a close and applicated in a state of the ST. It's place and applicated in a place and applicated

Considered

The collection of efformation is required by 20 CER 157 and 168. The efformation is required to below or date, belowed to the public which is the first period to 100 CER and 150 CER and

PTC/SB/08A (07-05)
Approved for use through 07/31/2006.0MB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless during a valid OMB control number. Substitute for form 1449A/PTO Complete if Known

ibstitute fo	r form 14	49A/PTO			Complete if Known			
		NFORMATION DISCLOSU STATEMENT BY APPLICAL  (use as many sheets as necessary 4 of of nickulen name of the action to the minute of		Application Number 10/534,660				
	et 4 of  NON F  Include name of the as  Cite Rem (book, magazine, jo	N DISCLOSURI	E	Filing Date	11/28/2005			
	ST/	ATEMENT I	BY APPLICAN	Г	First Named Inventor	Gunther Harth		
					Group Art Unit	1617		
	(u	se as many sh	eets as necessary)		Examiner Name	Unassigned		
Sheet		4	of	5	Attorney Docket Number	51326-00005 NAT		
					TURE DOCUMENTS			
xaminer Initials	Cite No.1			nal, senal, sympos	TTERS), fille of the article (when appr num, catalog, etc.), date, page(s), volu dior country where published,		T <sup>2</sup>	

Examiner Initials	Cite No.1	Rem (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Griffith et al., "Differential inhibition of glutamine and γ-glutamylcysteine synthetases by α- alkyl analogs of methionine sulfoximine that induce convultions," J. Biol. Chem. 253:2333-8 (1978)	
		Griffith et al., "Inhibition of glutathione biosynthesis by prothionine sulfoximine (S-n Propyl- Homocysteine Sulfoximine), a selective inhibitor of η-glutamylcycteine synthetase," J. Biol. Chem. 254:1205-10 (1979)	
		Griffith et al., "Potent and Specific Inhibition of Glutathione Synthesis by Buthionine Sulfoximine (S-n-Butyl-Homocysteine Sulfoxime)," J. Biol. Chem. 254:7558-60 (1979)	
		Griffith et al., "Vitamin C protects adult guinea pigs against tissue damage and lethality caused by buthionine sulfoximine-mediate glutathione depletion," FASEB J. 5:A1182 (1991)	
		Griffith, Amino acid sulfoximines: a-ethylmmethionine sulfoximine. Meth Enzymol 143:286- 91, 1987	
		Griffith et al., Resolution of cysteine and methionine enantiomers, Meth Enzymol 143:166- 72, 1987	
		Harth et al., "Treatment of Mycobacterium tuberculosis with antisense oligoucleotides to glutamine synthetase mRNA' inhibits glutamine synthetase activity, formation of the poly-L- glutamine/glutamate cell wall structure, and bacterial replication," Proc. Natl. Acad. Sci. USA 97:418-23 (2000)	
		Hoerlein "Glufosinate (phosphothricin), a natural amino acid with unexpected herbiciedal properties," Rev. Environ. Contamin. Toxicol. 138:73-145 (1994)	
		Liaw et al., "Structural Model for the Reaction Mechanism of Glutamine Synthetase, Based on Five Crystal Structures of Enzyme-Substrate Complexes," Biochemistry 33:675-81 (1994)	
		Logusch et al., "Inhibition of Escherichia coli glutamine synthetase by α- and γ-substituted phosphinotricins," Biochemisty 29:366-72 (1990)	
		Logusch et al., "Substrate variability as a factor in enzyme inhibitor design: Inhibition of ovine brain glutarnine synthetase by α- and γ-substituted phosphinothricins," Biochemistry 28:3043-51 (1989)	
		Manning et al., "Identification of L-Methionine-S-sulfoximine as the Diastereomer of L- Methionine-SR-sulfoximine that Inhibits Glutamine Synthetase," Biochemistry 8:2681-5 (1969)	
Examiner Signature		Date Considered	

Signature

Considered I delivery projects, whether are claims in conformance on DEST-DES Data for these projects of all continues are delivery projects. The project is applicated. Purples of the project in construction in paginate 1. Paginate in response can project in paginate 1. Paginate in response can project in paginate 1. Paginate in response can page 1. Paginate in paginate 1. Paginate in response can page 1. Paginate in paginate 1. Paginate in response can page 1. Paginate in paginate 1. Paginate in paginate 1. Paginate in paginate

This collection of information is required by 27 CFR LST and LST. The efformation is required to define or referm a beautiful by the guide velocity in the file part by the LSTEP OF processor and application. Confidencing in a symmetry to 30 LST CST and 75 CFR LST. This is continued in the 25 December to be compatible, described by the LSTEP OF THIS IN the confidence is not advantaged to define or compatible that the processor and application of the thin LSTEP OF THIS IN the confidence is not applicated by the confidence is not applicate in the confidence is not applicated by the confidence is not ap

PTO/SB/08A (07-05)
Approved for use through 07/31/2006.OMB 0651-0031

Patient and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
Substitute for form 1449APFO
Commister if Known

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Shoot

| Application Number | 10/534,650 | Filing Date | 11/28/2005 | First Named Inventor | Gunther Harth | Group Art Unit | 1617 | Examiner Name | Unassigned | Attorney Docket Number | 51/28/20005 NAT |

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	include name of the author (in CAPITAL LETTERS), filte of the article (when appropriate), title of the fern (book, magazine, journal, senal, symposaum, catalog, otc.), dake, page(s), volume-issue number(s), publisher, oty and/or country where published,	T <sup>2</sup>
		Matsumura et al., "Glufosinate ammonium induces convulsions through N-methyl-D- aspartate receptors in mice." Neurosci. Lett. 304:123-5 (2001)	
		McBean "Inhibition of glutamate transporter and glial enzymes in rat striatum by glioxin, [alpha]aminoadipate," Br. J. Pharm., 113:536-40 (1994)	
		Meister "Mitochondrial changes associated with glutathione defiency," Biochim. Biophys. Acta. 1271:35-42 (1975)	
		Nakaki et al., "Glufosinate ammonium stimulates nitric oxide production through N-methyl D-aspartate receptors in rat cerebellum," Neurosci. Lett. 290:209-12 (2000)	
		Proler et al., "The methionine sulfoximine syndrome in the cat," Epilepsia 3:117-30 (1962)	
		Rowe et al., "Identification of L-Methionine-S-Sulfoximine as the Convulsant Isomer of Methionine Sulfoximine," Proc. Natl. Acad. Sci. USA 66:500-6 (1970)	
		Tate et al., "Glutamine Synthetases of Mammalian Liver and Brain. In the Enzymes of Glutamine Metabolism," (S. Prusiner and E.R. Stadtman, eds.) Academic Press, NY 77-127 (1973)	
		Tokutake et al., "Design, Synthesis and Evalution of Transition-state Analogue Inhibitors of Escherichia coli y-Glutarnylcysteine Synthetase," Biorganic Med. Chem. 6:1935-53 (1998)	
		Tumani et al., Purification and immunocharacterization of human brain glutamine synthetase and its detection in cerebrospinal fluid and serum by sandwich enzyme immunoassav." J. Immonol. Meth. 188:155-63 (1995)	
		Winholz et al., ed., "The Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals, Tenth Ed.," Pub. Merck & Co., Inc. Rahway, N.J. USA, pp. 745-6 Abstract No. 5032 (1983).	
			├
			-
_			

Examiner	Date
Signature	Considered

"DWING It that in there considered, wholve or not classics in contaments with BFCP GED. Date fine framage classics if not in contaments and not considered. Include copy of this form with next communication is applicated. Applicated in contaments are presented in the present are contaments are presented in the contaments are presented in the present are contaments.

The collection of information is required by \$7.078.1 LB and 128. The effection is required to before or from a benefit by the public victim in it to the reflection in the production of the pr